Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
Dainippon Sumitomo Pharma (DSP), Mitsubishi Tanabe Pharma Corporation (MTPC), and its consolidated subsidiary Yoshitomiyakuhin Corporation announced on December 1 that DSP and Yoshitomiyakuhin will terminate a copromotion agreement between them for DSP’s atypical antipsychotics Lonasen (blonanserin) and Lullan (perospirone HCL)…
To read the full story
BUSINESS
- Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
- Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
- iPark, Taiwan’s ITRI Ink MOU to Boost Biotech Collaboration
April 23, 2026
- AbbVie, BioLabs Partner to Support Japan Biotech Startups
April 23, 2026
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…